Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael

Showing results (1211-1220 of 1,257) with videos related to

Pageof 126
Sort By:
International Journal of Cardiology|June 22, 2017
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trialsGianluca Campo, Rita Pavasini, Giampaolo Morciano, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Open Heart|October 17, 2022
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular diseaseSteven E Nissen, Kathy Wolski, Leslie Cho, et al.
Nature Medicine|May 13, 2024
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialDonna H Ryan, Ildiko Lingvay, John Deanfield, et al.
Circulation|September 5, 2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes, Michael Savage, J-M LaBlanche, et al.
Diabetes Care|June 22, 2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT TrialSteven E Kahn, John E Deanfield, Ole Kleist Jeppesen, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Pageof 126

Showing results (1211-1220 of 1,257) with videos related to

Sort By:
Pageof 126
International Journal of Cardiology|June 22, 2017
Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trialsGianluca Campo, Rita Pavasini, Giampaolo Morciano, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
JAMA|August 12, 2004
Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialA Michael Lincoff, Neal S Kleiman, Dean J Kereiakes, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
JAMA|February 18, 2003
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialA Michael Lincoff, John A Bittl, Robert A Harrington, et al.
Open Heart|October 17, 2022
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular diseaseSteven E Nissen, Kathy Wolski, Leslie Cho, et al.
Nature Medicine|May 13, 2024
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialDonna H Ryan, Ildiko Lingvay, John Deanfield, et al.
Circulation|September 5, 2002
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialDavid R Holmes, Michael Savage, J-M LaBlanche, et al.
Diabetes Care|June 22, 2024
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT TrialSteven E Kahn, John E Deanfield, Ole Kleist Jeppesen, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Pageof 126